Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

134.08 -0.21 (-0.16%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,359,089
Open	134.07
Bid (Size)	132.97 (100)
Ask (Size)	135.00 (1,000)
Prev. Close	134.29
Today's Range	133.95 - 134.32
52wk Range	34.34 - 134.32
Shares Outstanding	56,367,802
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders

July 14, 2026

From Halper Sadeh LLC

Via GlobeNewswire

What This Apogee Insider Move Might Mean After a 247% Stock Run ↗

July 12, 2026

Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.

Via The Motley Fool

Performance

YTD	+76.9%	+76.9%
1 Month	+57.3%	+57.3%
3 Month	+48.1%	+48.1%
6 Month	+66.0%	+66.0%
1 Year	+249.4%	+249.4%

More News

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗

July 11, 2026

Via The Motley Fool

Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress ↗

May 11, 2026

Via Chartmill

The Dividend ETF Quietly Outperforming the S&P 500 ↗

July 07, 2026

Via The Motley Fool

Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders

July 02, 2026

From Ademi LLP

Via GlobeNewswire

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗

June 30, 2026

Via The Motley Fool

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

June 24, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders

June 23, 2026

From Halper Sadeh LLC

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

June 23, 2026

Via Chartmill

Why AbbVie Stock Jumped Today ↗

June 22, 2026

Via The Motley Fool

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗

June 22, 2026

Via The Motley Fool

Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer ↗

June 22, 2026

Via The Motley Fool

Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗

June 22, 2026

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

June 22, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Which stocks are moving on Monday? ↗

June 22, 2026

Via Chartmill

Monday's session: gap up and gap down stocks ↗

June 22, 2026

Via Chartmill

APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

June 22, 2026

From Halper Sadeh LLC

Via Business Wire

These stocks that are showing activity before the opening bell on Monday. ↗

June 22, 2026

Via Chartmill

Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding ↗

June 10, 2026

Via MarketBeat

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing ↗

June 04, 2026

Via MarketBeat

Apogee Therapeutics to Participate in Upcoming June Conferences

May 28, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

May 27, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

May 27, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

May 26, 2026

From Apogee Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?

Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?

Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?

The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market

What is the current price of Apogee Therapeutics, Inc. - Common Stock?

The current price of Apogee Therapeutics, Inc. - Common Stock is 134.08

When was Apogee Therapeutics, Inc. - Common Stock last traded?

The last trade of Apogee Therapeutics, Inc. - Common Stock was at 07/16/26 04:00 PM ET

What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?

The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 7.56B

How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?

Apogee Therapeutics, Inc. - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.